Clincosm LogoSign in Get a demo

Sensitivity of Alternative NRL972 Detection Methods in Healthy Subjects

Sponsor
Norgine (Industry)
Overall Status
Completed
CT.gov ID
NCT01164332
Collaborator
(none)
32
Enrollment
1
Location
2
Arms
16
Duration (Months)
2
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The disposition of NRL972 after a 15-second intravenous injection of 2 mg NRL972 is distinctly slower in patients with hepatic cirrhosis and acute hepatitis than in healthy control subjects. NRL972 appears to be a suitable investigational marker of hepatic transporter clearance dysfunction.

Although the pharmacokinetics of NRL972 provide a reliable differentiation between subject groups, this approach relies on precisely timed sampling of venous blood, cautious preparation, handling and on-site storage of plasma samples, the transfer of samples to a central laboratory for analysis, and the availability of a validated assay procedure.

For these reasons, there is interest in developing and validating alternative methods for determining the concentration of NRL972 in venous blood. Two such methods have been developed to date, but their utility in determining NRL972 pharmacokinetics has yet to be established.

Condition or Disease Intervention/Treatment Phase
  • Other: NRL972
 Phase 1

Study Design

Study Type:
Interventional
Actual Enrollment :
32 participants
Allocation:
Non-Randomized
Intervention Model:
Crossover Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Investigation of the Sensitivity of Different Methods to Detect NRL972 in Healthy Volunteers During and After a 2-hour Intravenous Infusion of 10 and 30mg NRL972
Study Start Date :
Jul 1, 2010
Actual Primary Completion Date :
Nov 1, 2010
Actual Study Completion Date :
Nov 1, 2011

Arms and Interventions

Arm Intervention/Treatment
Other: Method A

First experimental detection method

Other: NRL972
Two-hour intravenous infusion of 5 and 15 mg per hour
Other: Method B

Second experimental detection method

Other: NRL972
Two-hour intravenous infusion of 5 and 15 mg per hour

Outcome Measures

Primary Outcome Measures

  1. Ratios of the plasma concentration at 30 minutes post-infusion to the concentrations at 10 and 15 minutes post-infusion [Up to 4 hours post-dose]

Secondary Outcome Measures

  1. Adverse events [Up to 4 hours post-dose]

  2. Vital signs [Up to 4 hours post-dose]

  3. ECG [Up to 4 hours post-dose]

  4. Clinical laboratory blood tests [Up to 4 hours post-dose]

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years to 45 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
Subjects meeting the following conditions will be eligible for enrolment:

  • Males or females (females of non-childbearing potential or of childbearing potential while taking medically appropriate contraception)

  • Caucasian

  • Age: 20 to 45 years

  • BMI 20 - 26 kg.m-2

  • Healthy based on the pre-study examination

  • Suitable veins for easy cannulation

  • Willing and able to provide informed consent

Exclusion Criteria:
Subjects of any of the following categories will be excluded from enrolment:

General - all subjects

  • Previous participation in the trial

  • Participant in any other trial during the last 90 days

  • Donation of blood during the last 60 days or a history of blood loss exceeding 300 mL within the last 3 months

  • History of any clinically relevant allergy

  • Presence of any acute or chronic infection

  • Presence or history of any relevant co-morbidity

  • Resting systolic blood pressure > 160 or < 90 mmHg, diastolic blood pressure > 95 or < 50 mmHg

  • Clinically relevant ECG-abnormalities, prolonged QTc with > 450 msec in males and > 460 msec in females in particular

  • Presence of any relevant abnormality in the laboratory safety tests, especially low haemoglobin, increased liver enzymes

  • Positive serology for HBsAg, anti HBc and anti HCV

  • Positive HIV test

  • Positive alcohol or urine drug test on recruitment

  • History of alcohol and/or drug abuse and/or daily use of > 30 g alcohol

  • Smoking more than 10 cigarettes/day or equivalent of other tobacco products

  • Use of prohibited medication

  • Suspicion or evidence that the subject is not trustworthy and reliable

  • Suspicion or evidence that the subject is not able to make a free consent or to understand the information in this regard

General - all females

  • Positive pregnancy test

  • Lactating

  • Not using appropriate contraception in premenopausal women

Contacts and Locations

Locations

Site City State Country Postal Code
1 Phase I-II study clinical of the Drug Research Center Ltd. Balatonfüred Hungary H-8230

Sponsors and Collaborators

  • Norgine

Investigators

  • Principal Investigator: Eva Peterfai, MD, Drug Research Center Ltd.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Norgine
ClinicalTrials.gov Identifier:
NCT01164332
Other Study ID Numbers:
  • NRL972-01/2010 (AMET)
First Posted:
Jul 16, 2010
Last Update Posted:
Jun 10, 2015
Last Verified:
Jul 1, 2011
Additional relevant MeSH terms:
Fibrosis

Study Results

No Results Posted as of Jun 10, 2015